Human IgG Heavy and Light Chain Cross-Adsorbed Antibody

Rabbit Polyclonal Conjugate DyLight® 800

Antigen Affinity Purified

Catalog No. A80-218D8

Lot No. A80-218D8-6

APPLICATIONS	IHC, ICC, Flow Cyt, IF
SPECIES REACTIVITY	Human. Minimum reactivity to mouse and rat
AMOUNT	1 ml
CONCENTRATION	0.5 mg/ml
STORAGE/SHELF LIFE	2 - 8°C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Phosphate Buffered Saline (PBS) containing 0.2% BSA and 0.09% Sodium Azide
FLUOROPHORE/PROTEIN	4.7
ISOTYPE	IgG
ORIGIN	USA
PRODUCTION PROCEDURES	Antiserum was cross adsorbed using mouse and rat immunosorbents to remove cross reactive antibodies. The antibody to human IgG was isolated by affinity chromatography using antigen coupled to agarose beads and conjugated to DyLight® 800. Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG. By immunoelectrophoresis and ELISA this antibody reacts specifically with human IgG and with light chains common to other human immunoglobulins. No antibody was detected against non-immunoglobulin serum proteins. Less than 1% cross reactivity to mouse and rat IgG was detected. This antibody may cross react with IgG from other species.
APPLICATIONS	Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

Immunohistochemistry	1:50 - 1:500
Immunocytochemistry	1:50 - 1:500
Flow Cytometry	1:50 - 1:200
Immunofluorescence	1:50 - 1:500

APPLICATION NOTES	Not all listed applications have been specifically tested by our laboratory. DyLight® 800 is excited at 770 (in PBS) and emits at 794 (in PBS). DyLight® is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
ADDITIONAL INFO	https://www.fortislife.com/p/A80-218D8 Use the link above to view SDS, a current list of citations, and other product specific information.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.

Michael Spencer, PhD Date: December 16, 2022